Skip to main content

Perrigo Company Value Stock - Dividend - Research Selection

Perrigo

ISIN: IE00BGH1M568 , WKN: A1XAEY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Perrigo: This 11% Yielder Should Cut The Dividend

2026-06-06
Perrigo (PRGO) stock outlook: high leverage and shaky dividend coverage put a 10.9% yield at risk. Read here for a detailed investment analysis.

Dividend Champion, Contender, And Challenger Highlights: Week Of May 24

2026-05-22
Get this weekly dividend update on Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates.

Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y

2026-05-07
PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.

Assessing Perrigo (PRGO) Valuation After Weak Q1 Results And Lowered Guidance

2026-05-07
Perrigo (PRGO) stock is in focus after the company reported first quarter sales of US$969.2 million and a net loss of US$398.6 million, which widened sharply from the prior year. See our latest analysis for Perrigo. The weak first quarter numbers and recent investigation headlines come after a difficult stretch for investors, with a 1 year total shareholder return of 50.36% and a 5 year total shareholder return of 67.42%. However, the recent 1 month share price return of 15.77% hints at short...

Perrigo Company plc Q1 2026 Earnings Call Summary

2026-05-07
Moby summary of Perrigo Company plc's Q1 2026 earnings call

Diamond Hill Small-Mid Cap Strategy Q1 2026 Portfolio Activity

2026-05-07
We initiated a position in Antero Resources, a natural gas exploration and production company, to gain exposure given our constructive long-term outlook for US natural gas.

Earnings Scheduled For May 6, 2026

2026-05-06

Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript

2026-05-06
Perrigo Company plc (PRGO) Q1 2026 Earnings Call May 6, 2026 8:30 AM EDTCompany ParticipantsEric JacobsonPatrick Lockwood-Taylor - President, CEO &...

Transcript : Perrigo Company plc, Q1 2026 Earnings Call, May 06, 2026

2026-05-06
Presentation Operator MessageOperator Good morning, ladies and gentlemen, and welcome to Perrigo Q1 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded on...

Perrigo (PRGO) Q1 Earnings Beat Estimates

2026-05-06
Perrigo (PRGO) delivered earnings and revenue surprises of +10.26% and -4.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?